Acquisition / mergerNotableFiled on BSE ·

Dr. Lal PathLabs approves Q1 FY2026-27 results, INR 5 interim dividend and stock options

Dr Lal Pathlabs · Healthcare Services

Arthneeti Research DeskPublished 1 min read
₹798 CrAcquisition / merger

Key highlights

  • Quarter ended June 30, 2026: consolidated revenue from operations INR 7,977 million, profit for the period INR 1,705 million; standalone INR 7,644 million and INR 1,659 million.
  • Interim dividend of INR 5 per share (50% on INR 10 face value), record date July 30, 2026; to be paid within 30 days of declaration.
  • 119,300 stock options granted on July 24, 2026 under Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025, exercisable for 5 years from vesting.

Why it's rated notable: the year-on-year change is 27% (20% to 50%)

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

Corporate Action-Board approves Dividend

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Dr Lal Pathlabs

Other acquisition / merger filings this fortnight

All acquisition / merger filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.